Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This study is intended to evaluate the efficacy and safety of ANX005 administered by intravenous (IV) infusion to participants recently diagnosed with Guillain-Barré Syndrome (GBS). The total duration of study participation is approximately 6 months.
Epistemonikos ID: e96e37fec0fc4a4a0bd6e4c38339ac4063a72dbe
First added on: May 08, 2024